Author Archives: admin


The fight against blood cancer continues – Sherbrooke Record

Calling all hockey fans. The Hockey Fights Cancer fundraiser for Maisonneuve Rosemont Hospital will take place this Sunday, Feb. 23 at 3:30 p.m. in the Bishops arena. Four teams of friends, firefighters and plain old hockey fanatics will take the ice to help fund cutting edge research in stem cell therapy to treat blood cancer. The tournament is free and open to the public, and anyone interested in supporting the cause or just watching the games is welcome to attend. The tournament started last year after local firefighter Eric Mackeage, diagnosed with a rare form of blood cancer, received treatment at the Maisonneuve Rosemont Hospital. When friends of Mackeages stepped up wanting to help, it was decided the best way would be to raise money to support the research that Mackeage believes saved his life. Im an experiment, Mackeage said. Firefighters are at an increased risk of developing the type of cancer Mackeage was diagnosed with. See full story in the Thursday, Feb. 20 edition of The Record.

Read more:
The fight against blood cancer continues - Sherbrooke Record

Survivor Legend Ethan Zohn Discusses His Journey Through Cancer and Back to the Island – Parade

This past Wednesday, millions of Survivor fans got to see 20 previous winners from the reality shows storied past return for another shot at victory and a $2 million prize. And while each of them had a journey to getting back to the island, season 3 winner Ethan Zohn may have the most inspirational story of them all. Because up until seven years ago, not only was it up in the air whether Ethan would be playing Survivor again in 2020, it was unlikely he would even be alive to see season 40.

In 2009, five years after his last Survivor appearance, Ethan was diagnosed with a rare type of cancer called CD20-positive Hodgkins lymphoma. He underwent several treatments since his diagnosis and was declared cancer-free in late April 2010. Then, after nearly 20 months of remission, cancer returned in his chest. Not to be deterred, Ethan continued to undergo stem-cell transplants, all the while doing charity work to promote his cause, as well as his charity Grassroot Soccer, which uses soccer to raise money and awareness to fight HIV/AIDS. In March 2013, Ethan officially declared he was cancer-free once more and has been in remission ever since. With a clean bill of health, hes now ready to return to the game that changed him forever, with a new outlook on life.

Ethan talks with Parade.com about the experience of engaging with both Survivor and the fandom after more than a decade away, the struggles he underwent after becoming cancer-free, and his decision to use his time in the spotlight to give back.

Related: Survivor Season 40: Everything We Know So Far (Including Who Was Voted Out)!

This time last week, you got to watch your return with a special screening of the premiere on the big screen in LA What was that experience like, the culmination of everything you went through to this point?Watching myself, I cant believe they make us run around in our underwear! Ill just put that out there. Im like, Jeff, they know were not shipwrecked. We get it. Give us some bathing suits, buddy! Nobody wants to watch anyones junk flop around. (Laughs.)

But watching myself on TV was a rush. Its a snapshot of my life. Its my highlight reel, and this is my song. Being here is just another chapter in this incredibly blessed life that Survivor has given me. Ive never watched the show with such a live audience, with fans cheering for different people and moves. It heightens the excitement for me. I realize how lucky I am and the moment we have right here. Im just trying to drink it all in and have so much fun.

Whats it been like to engage with the fan community, considering how different it looks between now and when you first played?When we played the game, it was like we were playing underwater compared to now. We had no idols, no clues, no ways to get back into the game, nothing. To take that one step further, we had no social media. We had printed media, radio, maybe some television spots. The way in which information is passed around is like light speed. That is indicative of the way the world works and how the games played. We delved deep into personal relationships, honor, integrity, trust, teamwork, and survival. We depended on each other to survive daily out there in Africa. Now its like boom, boom, blindsides, backstabs, idol clues. Its fast-paced, rocket fuel injected into the game of Survivor both inside and outside the show.

For me, just trying to keep up with social media is a thing in and of itself! (Laughs.) Im trying to figure out whats going on right now. But its been fun to interact with it because, surprisingly, a lot of fans Ive been connecting with are young. They were either extremely young or not alive when I was on the show. So to see a new generation of fans getting excited about the greatest show on earth is pretty exciting.

Youve been considered one of the most well-liked and revered players in Survivor history. What has been your reaction to that label?It feels wonderful, to be honest. (Laughs.) It lets me reminisce about my past in a way thats really fun and exciting for my family and me. I definitely didnt drop off the face of the earth, but Ive been in the public eye recently more as a cancer survivor than a Survivor player. So its really fun and exciting. Im very appreciative of what this show has enabled me to do in my life. So coming back on was wonderful. Its also paying tribute to the life the show has given me, to everyone who has come before and after me who made this show what it is today.

I specifically remember the first second of the game, when we lined up on the beach. I looked down and saw $21 millionbecause Sandras won twiceas well as a history lesson. Youre looking at each person and seeing 20 years of my life, of Jeffs life, of everyones lives. Its rare that any TV show has the shelf life Survivor has. I remember in season 3, people say, Oh, this is the last season. Theres no way this is going to go another season. (Laughs.) September 11th happened, and nobody wanted to see a show called Survivor and see people suffer. Now look at us, 20 years later!

Though youve been away from Survivor for a while, you certainly havent strayed away from reality television at large. What drove you to want to appear on other shows, even if they werent on an island?Right place, right time. It was the start of reality television as a genre. All these new shows were coming out, and having been on Survivor, most of the time, they were celebrity reality shows. I just said yes to everything. I never thought it would last that long. So I thought, Im going to get in and have as much fun as I possibly can. Because I never know when this is going to end. So I said yes to every single opportunity possible. Why not?! (Laughs.) Plus, its always a good opportunity for me. I could wear a Grassroot Soocer t-shirt, or talk about my experience with cancer.

Its good to have something valuable in your life that isnt reality TV. I went on reality TV because it was a crazy adventure. I wanted to compete at the highest level in front of millions of people. Youre never going to get that anywhere. I didnt grow up watching Survivor dreaming of being on, like an Adam Klein. People like him, Michele, Wendell, and Ben grew up on when I was on the show, and here they are coming out to play again because its been their lifelong dream to be on Surivor. My lifelong dream was to be a professional soccer player. Once I accomplished that, this was the icing on the cake.

Its interesting you talk about never knowing when your reality TV career would end, given the way your life went. I cant imagine what your first thought was when you received your initial cancer diagnosisGetting diagnosed as a young adult at 35 years with a rare form of blood cancer was completely shocking to me. My only connection to cancer was through my father, who passed away when I was 14. So I only thought, Cancer = death. I was completely frightened and confused, as you can imagine. At that point, all my other friends were just starting their lives. They were beginning jobs and families, moving to new homes and towns. I was forced to press pause on my life, while everyone else was starting theirs. That was difficult for me. But coming out of the cancer diagnosis was more difficult for me personally.

Related: Survivor Winners at War: Lex van den Berghe on Amber Mariano and Old School Tactics

Can you elaborate on that?When you get diagnosed, and the doctor tells you to do something or youll die, you do it. Theres no choice; its not that hard. But then, when youre deemed healthy and in remission, all the doctors and nurses go away. And your friends start to pull away. Thats when it really got hard. Dealing with the anxiety and the fear of relapse, the dump trucks full of uncertainty, the scars that need healing. Now Im a young adult with no job. Im infertile; whos going to marry me? Is it going to come back? Theres all this stuff in your mind as a young man that an older adult doesnt face. I had to get to a point in my life where I was mentally clear, physically strong enough, and spiritually open to having an experience like Survivor. Thats the win for me. Just getting to the starting line is probably harder than anything Ill have to do for the rest of my life.

Obviously Survivor and fighting cancer are like apples and orange. But is there anything you pulled from that experience mentally or emotionally that helped you during your treatments?I do think my time on Survivor enabled me to learn how far I can push my body. Mentally, physically, spiritually, environmentally, socially. On Survivor, you push yourself to the max, and then you have to go even further. Coming into cancer, Im like, Okay, Ive suffered before. I know this is going to suck, but Ive been here before. Youve just got to take it day by day and minute by minute. You never know whats around the corner, whether it be an Immunity Challenge or a clinical trial.

Survivor is a game of relationships. Youve got to make friends with these people, but friendship is based on trust, and you cant really trust anyone. With cancer, you are surrounded by so many people who love you. But it is a lonely feeling. No one knows what its like to have cancer unless youve been through it yourself. Even then, everyones experience is different based on who you are. There is loneliness out there on Survivor. Even though you have a tribe and alliances, the result is having fewer and fewer people around you. The concept of community exists at a level. But in the back of everyones minds, they want you dead. (Laughs.) So does cancer. There are surprisingly some parallels.

When you get the call to go out for season 40, what went through your head, considering how much your life has changed from the last time you played?The game has changed, and so have I. (Laughs.) Its not better or worse now; its just different. Any good player in any sport has to adapt and be open to playing with the rules that exist for that specific game at that moment. I had gotten to a point where I was comfortable in life, with my wife and my two cats in New Hampshire. Im not the 27-year-old who doesnt care what happens to him anymore. Im now playing with the fact that Ive had to go through cancer and stem cell treatment twice. No one else has brought that kind of baggage into the game. Yes, everyone out there has a story and challenges weve overcome to get to where we are. I dont think anyone has had the health challenges that Ive had going out there. I was a little nervous about leaving the world I lived in to play that game, to be honest.

Once you made that decision, how did you make sure you were ready to go back into the game?I knew I had to do some catching up! I knew I had to get off the couch and stop smoking weed; cannabis and CBD have been huge in helping my post-cancer anxiety medically speaking. I left New Hampshire, because they called me in January and I knew I couldnt swim in a frozen lake. My wife and I moved down to Atlanta and I started training outside. I was swimming, doing puzzles, reading body language and lip reading books. I met with my shrink; my wife hid idols in the forest for me to find every day. I thought, If Im going to do this, to ease my fears that Im an old-schooler who has no place in the modern game, I want to get ready.

Related: Survivor Winners at War: Reed Kelly Talks Natalie Anderson and the Power of Partnerships

What role has the show served in your life, especially as the years passed between appearances? I know youve told the story about receiving a stem cell treatment while you were watching the Heroes vs. Villains premiere.Survivor is a wonderful word to describe me for a lot of different reasons. Its been a constant in my life. Im still known as the Survivor guy. I do a lot of speaking engagements, and my notoriety comes from the fact that I was on Survivor. Im not trying to hide that fact. Survivor changed my life. It sent me on a trajectory and enabled me to do so many things I would have dreamed of doing. I am incredibly grateful and appreciative of what this show has offered me.

Not only is the show creating fans around the world, but they are also saving lives. This show is completely responsible for the fact that I was able to co-found Grassroot Soccer. I played professional soccer in Zimbabwe leading up to my time on Survivor: Africa. During the show, I played hackeysack with the children in a local village. It was a real-life moment in the middle of this cutthroat game. When I won the money, I wanted to do something great with that. I met up with some buddies of mine, and we co-founded Grassroot Soccer. Were an adolescent health organization that has programs running in 63 countries and graduated 2.3 million kids, all because of Survivor.

Let me take that one step further for you. When I got cancer, we had just lost [Palau contestant] Jennifer Lyon. We were battling at the same time, and she didnt make it, unfortunately. In response to that, I created Survivor Stand Up to Cancer, which was a partnership between the show and the cancer research organization. Every year, props are auctioned off, and the proceeds go to cancer research. Some of the money raised from 2009 to 2012 was used to fund an experimental new drug that saved my life. Talk about full circle! This show is so much bigger than people imagine, especially in my life.

You get the chance to come back to the show that has meant so much to you. Your feet hit the sands of Fiji, and you realize youre playing Survivor again. Describe that feeling for me.Just thinking about it gives me chills. Theres so much emotion. My heart was pumping; my brain was going crazy. Theres a lot of pressure that Im putting on myself, the pressure to perform well, make alliances, not look stupid, and win. All this stuff is going through your head at that exact moment. The games about to start; Jeff Probsts waiting for you. Youre just walking into one of the most uncomfortable comfortable situations. Ive dreamed of this moment, hoping it unfolds positively. It was emotional. Its a perfect little bow on this amazing life that Survivor has given me.

Celebrity interviews, recipes and health tips delivered to yourinbox.

See the rest here:
Survivor Legend Ethan Zohn Discusses His Journey Through Cancer and Back to the Island - Parade

A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself – Newswise

MEDIA CONTACT

Available for logged-in reporters only

R01DK081113, U01DK103152, P50CA127003; Cell Stem Cell

A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself

Newswise BOSTON Deep within the lining of the human intestine lies the source of the organs ability to renew itself and recover from damage: intestinal stem cells (ISCs), lodged in pockets of tissue called crypts, generate the cells that continuously repopulate the intestinal lining. Even the stem cells themselves have a safety net: when theyre damaged, healthy replacements appear in less than a week.

For years, scientists have debated how the ISCs re-emergence occurs. Some have held that the intestine keeps a pool of ISCs on reserve a kind of backup-backup supply to replenish the cache of front-line ISCs that have been lost. Others have maintained that something more involuted is as work: The ISCs, like queen bees, give rise to more specialized, or differentiated, progeny in this case, daughter cells that form the inner lining of the intestine. When the ISCs are damaged, this school of thought held, the daughter cells reverse course and de-differentiate reverting into the ISCs from which they arose.

A new study by Dana-Farber Cancer Institute scientists comes down solidly on the latter option.

Published online today by the journalCell Stem Cell, the researchers found that ISCs and their daughter cells have a strikingly reciprocal relationship: under normal conditions, ISCs differentiate into daughter cells, and, if the ISCs are lost, the daughter cells simply reverse course and become ISCs. Our findings suggest that the restoration of intestinal stem cells occurs entirely by the process of de-differentiation, says the studys senior author, Ramesh Shivdasani, MD, PhD, of Dana-Farber, Brigham and Womens Hospital (BWH), and the Harvard Stem Cell Institute. We showed theres no need for a reserve set of ISCs.

Bolstering their findings, the researchers were also able to capture the de-differentiation process in real time. When cells begin to de-differentiate, they switch on a gene that that allows them to be isolated and collected with laboratory techniques, Shivdasani explains. Through this process, researchers were able to capture the cells along a continuum of de-differentiation. Shivdasani likens it to a baseball play in which a runner is tagged out between first and second base.

Heavy turnover

The intestine is one of just three tissues in the body, along with the skin and blood, in which cells are constantly turning over dying and being replaced by freshly made cells. They share this quality because they are the tissues most intimately in contact with material from the environment, and therefore with potentially harmful substances. The constant turnover, its thought, is a way to prevent toxic substances from having lasting effects on cells and their offspring.

The crypts that hold ISCs are, in a sense, misnamed. Far from being enclosures where dead cells are entombed, they are the sites where ISCs daily generate the billions of daughter cells that take the place of defunct intestinal cells.

One of the chief characteristics of ISCs is that they are extremely radiosensitive, or vulnerable to radiation. People exposed to high levels of radioactivity, in the form of nuclear fallout, for example, can suffer severe intestinal damage because the loss of ISCs halts production of cells to regenerate the damaged tissue. But if ISCs succumb easily to radiation, they also make a rapid return. Patients with radiation-induced intestinal damage who can be kept alive for a week often recover as their ISC levels bounce back.

To determine whether this rebound is due to a reserve stockpile of ISCs or to de-differentiation of daughter cells, Shivdasani and his collaborators performed a kind of time-lapse experiment. They treated a collection of ISC cells with the drug tamoxifen, which caused the cells and their offspring to become fluorescent. They waited 48 hours for the label to take hold, then killed the ISC cells. If the daughter cells were indeed de-differentiating, any ISC cells produced after that point would be fluorescent.Thats exactly what researchers found.

While scientists have been able to convert many kinds of differentiated cells into stem cells using laboratory techniques, Shivdasani and his colleagues discovery demonstrates that de-differentiation ismore than a curious act of nature; it is the principal means to restore damaged stem cell in the intestine. Its not known whether cells in other organs and tissues have this capability, but it remains an open avenue of investigation.

It also isnt clear how the crypt knows that stem cells have died and need to be replaced, Shivdasani remarks, or how the daughter cells receive the signal to de-differentiate. This is a subject were currently exploring.

The lead author of the new paper is Kazutaka Murata, PhD of Dana-Farber and BWH. Co-authors are Unmesh Jadhav, PhD, and Alessia Cavazza, PhD, of Dana-Farber and BWH; Shariq Madha, Justin Dean, Kai Wucherpfennig, MD, PhD, and Franziska Michor, PhD, of Dana-Farber; and Johan van Es, PhD, and Hans Clevers, MD, PhD, of Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Centre, Utrecht, the Netherlands. The research was supported by the National Institutes of Health (grants R01DK081113, U01DK103152, and P50CA127003) and gifts from the Lind family.

###

Dana-Farber Cancer Institute is one of the worlds leading centers of cancer research and treatment. It is the only center ranked in the top 5 of U.S. News and World Reports Best Hospitals for both adult and pediatric cancer care.

Dana-Farbers mission is to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. We provide the latest in cancer for adults through Dana-Farber/Brigham and Women's Cancer Care and for children through Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

Dana-Farber is dedicated to a unique and equal balance between cancer research and care, translating the results of discovery into new treatments for patients locally and around the world.

See the original post:
A case of reverse development: Dana-Farber scientists solve long-debated puzzle of how the intestine heals itself - Newswise

FDA Scoffs at Third Way Forward in Stem Cell Therapy – Pain News Network

Gimble and his co-authors recommend the FDA re-evaluate how it categorizes tissues as structural or cellular to recognize the different safety profiles of stem cells products. They also think the FDA should work with accreditation agencies like AABB and FACT to develop meaningful accreditation standards, along with a national registry for stem cell therapies.

This measured third way seeks to carve a compromise between the FDAs regulationist faction and wild west stem cell providers -- a new ideological center that synthesizes the aspirations of two opposing parties in an effort to achieve a compromise.

It must be stated that there are serious questions as to whether the authors proposed polarity is in fact an artifice created for the specific purpose of legitimizing their third way. Upon serious inspection, the authors stated dangers of stem cell clinics may actually be a disingenuous straw man created for their own business interests.

To promote their own agenda and to gain favor with the FDA, Gimble and his co-authors seem to have thrown stem cell clinicians like Dr. Mark Berman under the proverbial bus. Berman, who is a defendant in a FDA lawsuit over his use of autologous cells, recently won a victory in federal court. The judge found that the FDA may not have regulatory authority over Bermans procedures and that a trial needs to be held to resolve the issue.

Nevertheless, the impetus behind the authors recommendations is to move forward with bringing stem cells to patients faster and in a safer manner. Regrettably, the FDA does anything but take the authors seriously. In a lengthy response to the Gimble article, Dr. Peter Marks, Director of the FDAs Center for Biologics Evaluation and Research, merely reiterates the agencys firmly-established regulationist position.

After commending the authors for their desire to accelerate the scientific investigation and development of stem cell therapies, Marks demonstrates the FDAs backward-looking posture by stating the agencys regulation of stem cells is distinct from the practice of medicine and should be left alone.

This is an existing paradigm that has been in place for decades, Marks wrote. Autologous cellular therapies do hold tremendous promise, but they will only find their way into routine clinical practice to bring benefit to all patients if they are held to the same standards to demonstrate safety and efficacy as other unproven medical products.

Marks attempts to bolster his argument by citing patient safety, the dearth of research on adipose-derived stem cells and the unethical bad actor clinics that exploit desperate patients. However, the spirit of his position reveals a resistance to any sort of change whatsoever.

Marks and the FDA are living in the past. They consider your cells to be unproven medical products. Apparently, they have yet to realize that the stem cell poles have already shifted.

A. Rahman Ford, PhD, is a lawyer and research professional. He is a graduate of Rutgers University and the Howard University School of Law, where he served as Editor-in-Chief of the Howard Law Journal. Rahman lives with chronic inflammation in his digestive tract and is unable to eat solid food. He has received stem cell treatmentin China.

Visit link:
FDA Scoffs at Third Way Forward in Stem Cell Therapy - Pain News Network

BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 – Yahoo Finance

Conference Call and Webcast @ 8:00 a.m. Eastern Time Today

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.

2019 was a tremendous year for BrainStorm, with significant progress and achievements across all clinical and operational fronts, stated Chaim Lebovits, President and Chief Executive Officer of BrainStorm. Most importantly, we fully enrolled our pivotal, double blind, placebo-controlled Phase 3 trial of NurOwn for the treatment of ALS. We announced the trial conducted at six major U.S. medical centers of excellence for ALS, was fully enrolled on October 11, 2019, and on October 28, 2019 the Data and Safety Monitoring Board (DSMB), completed the second planned interim safety analysis for the first 106 patients who received repeat dosing of NurOwn in the Phase 3 trial. The DSMB concluded the trial should continue as planned without any clinical protocol changes. He added, In addition, one of the most prestigious peer-reviewed journals, Neurology, published NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results, bringing news of our investigational therapy to the global scientific community. And, just last week, we were happy to announce that the Company recently held a high level meeting with the U.S. Food and Drug Administration (FDA) to discuss potential NurOwn regulatory pathways for approval in ALS.

Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer of BrainStorm added, 2019 was also a very significant year for those who suffer from progressive Multiple Sclerosis (MS). In February 2019, we announced Cleveland Clinic would serve as our first contracted site for a Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn (autologous MSC-NTF cells) in participants with progressive MS (NCT03799718). We enrolled our first patient in March. We contracted with The Stanford University School of Medicine, The Keck School of Medicine of the University of Southern California, and the Mount Sinai Medical Center to further enroll patients. Dr. Kern added, The importance of our research in progressive MS was acknowledged by a $495,000 grant award from the National Multiple Sclerosis Society through its Fast Forward Program, and mid-December, the Data Safety Monitoring Board completed the first, pre-specified interim analysis, of safety outcomes for 9 participants and after careful review of all available clinical trial data, the DSMB unanimously concluded that the study should continue as planned without any protocol modification. As of December 31, 2019 we have enrolled 10 patients in the study (50% enrollment completed).

Fourth Quarter Corporate Highlights:

Financial Results for the Year Ended December 31, 2019 and Recent Updates

For further details on BrainStorms financials, including financial results for the year ended December 31, 2019, refer to the Form 10-K filed with the SEC today.

Conference Call on Tuesday, February 18th @ 8:00 am Eastern Time

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

Story continues

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. Brainstorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. Brainstorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor StatementStatements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: 862-397-8160pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED BALANCE SHEETSU.S. dollars in thousands(Except share data)

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands(Except share data)

See the original post here:
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 - Yahoo Finance

Data On Enlivex’s Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation…

Nes-Ziona, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company wasselected, for a scientific presentation of two posters: (i) Allocetra-OTS: Early Apoptotic Cells for Immune Homeostasis in Human Stem Cell Transplantation (HSCT) and for the Prevention of Graft Versus Host Disease (GvHD), and (ii) Apoptotic Cells Reprogram Resident Macrophages to Support Chimeric Antigen Receptor (CAR) T Cell Therapy Against Peritoneal Solid Tumor, at the Transplantation & Cellular Therapy Meetings Conference of the ASTCT and CIBMTR (TCT), held on February 19-23, 2020, in Orlando, Florida.

Allocetra-OTS: Early Apoptotic Cells for Immune Homeostasis in Human Stem Cell Transplantation (HSCT) and for the Prevention of Graft Versus Host Disease (GvHD)

Results from preclinical and clinical studiesy suggested that a single infusion of donor early apoptotic cells (Allocetra) as prophylaxis for GvHD in myeloablative HSCT is safe and potentially effective and led to 0% (0/6) of acute high grade II-IV GvHD in the two higher dosages compared to 52% in matched historical control. Enlivex is planning to initiate a Phase 2/3 multi-center, open-label, 2-arm study (ENX-CL-01-002), in Israel and Germany, that will evaluate the efficacy and safety of Allocetra-OTS (140x106cells/kg) with or without anti-thymocyte globulin (ATG) for the prevention of GvHD in subjects undergoing HLA-matched HSCT from an unrelated donor.

Apoptotic Cells Reprogram Resident Macrophages to Support Chimeric Antigen Receptor (CAR) T Cell Therapy Against Peritoneal Solid Tumor

Preclinical studies showed significantly increased duration of survival and overall survival for study subjects who were treated with the combination therapy, as compared to stand-alone solid tumor CAR-T therapy. The results of these preclinical studies showed that the mechanism of action significantly increased the anti-tumor macrophage population surrounding the human solid tumor microenvironment in the subjects who were treated with the combination therapy.

ALLOCETRATMby Enlivex was designed toprovide a novel immunotherapy mechanism of actionthat targets life-threatening clinical indications that are defined as unmet medical needs, includingprevention or treatment of complications associated with bone marrow transplantations (BMT) and/or hematopoietic stem cell transplantations (HSCT); organ dysfunction and acute multiple organ failure associated with sepsis; and enablement of an effective treatment of solid tumors via immune checkpoint rebalancing.

ABOUT ENLIVEXEnlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visit http://www.enlivex.com.

ABOUT EUROPEAN MOLECULAR BIOLOGY ORGANIZATIONThe TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT Meetings) are the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).

Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as expects, plans, projects, will, may, anticipates, believes, should, would, intends, estimates, suggests, has the potential to and other words of similar meaning, including statements regarding expected cash balances, market opportunitiesfor the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunitiesfor, ALLOCETRATMprograms, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivexs business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATMproduct line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivexs filings with the Securities and Exchange Commission, including under the heading Risk Factors contained in Enlivexs most recently filed Annual Report on Form 20-F. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT: Shachar Shlosberger, CFO Enlivex Therapeutics, Ltd.shachar@enlivex-pharm.com

View post:
Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation...

Personalized Medicine Market Worth $3.92 Trillion by 2026 – Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics – P&T…

DUBLIN, Feb. 20, 2020 /PRNewswire/ -- The "Global Personalized Medicine Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026, growing at a CAGR of 12.1% during the forecast period.

The efficient and advanced technology and higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

Based on the End-user, the hospital's segment is estimated to have a lucrative growth due to the lower cost personalized medicines availability in the hospitals. As the practice of personalized medicine becomes more widespread, hospitals will also experience the need to adapt. That does not mean every hospital and medical centre should try and drive the science, but they should be open to collaborations to facilitate such work.

The key vendors mentioned are Abbott Laboratories, Affymetrix Incorporated, Agendia N.V, Agilent Technologies, Inc, Amgen, Inc, Asuragen Incorporated, Bayer Healthcare Pharmaceuticals, Llc, Celera Diagnostics LLC, Celgene Corporation, Roche Diagnostics Corporation, Precision Biologics Incorporated, Siemens Healthcare Diagnostics, Inc, Sigma-Aldrich Corporation, Johnson & Johnson, Novartis AG, Decode Genetics Inc., Exact Science Corporation, Exagen Diagnostics Inc., GE Healthcare, and Genelex Corporation.

Key Questions Answered in the Report

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics3.1 Drivers3.2 Restraints

4 Market Environment

5 Global Personalized Medicine Market, By Product5.1 Introduction5.2 Diagnostics5.3 Personalized Medical Care5.4 Personalized Nutrition & Wellness5.5 Therapeutics

6 Global Personalized Medicine Market, By Technology6.1 Introduction6.2 Metabolomics6.3 Pharmacodynamics6.4 Pharmacogenetics6.5 Pharmacogenomics6.6 Pharmacokinetics6.7 Pharmacoproteomics6.8 Point-of-Care Testing6.9 Stem Cell Therapy

7 Global Personalized Medicine Market, By Therapeutic Area7.1 Introduction7.2 Autoimmune Diseases7.3 Blood Transfusion Safety7.4 Cancer Management7.5 Cardiovascular Diseases (CVD)7.6 Central Nervous System (CNS) Disorders7.7 Coagulation Therapy7.8 Diabetes7.9 Infectious Diseases7.10 Antiviral7.11 Neurology7.12 Psychiatry7.13 Oncology7.14 Immunology7.15 Respiratory

8 Global Personalized Medicine Market, By Distribution Channel8.1 Introduction8.2 Dietary Care Centers8.3 Hospital's Pharmacies8.4 Retail Pharmacies8.5 Other Distribution Channels

9 Global Personalized Medicine Market, By Application9.1 Introduction9.2 Biomarker Identification9.3 Clinical Research Applications9.4 Companion Diagnostics9.5 Health Informatics

10 Global Personalized Medicine Market, By End-user10.1 Introduction10.2 Academic Institutes10.3 Bio and Health Informatics Companies10.4 Clinical Care and Research Laboratories10.5 Contract Research Organizations10.6 Hospitals10.7 Molecular Diagnostic Laboratories and Testing Facilities10.8 Research Laboratories10.9 Service Providers10.10 Partner10.11 Venture Capitalists10.12 Other End-users

11 Global Personalized Medicine Market, By Geography11.1 North America11.2 Europe11.3 Asia-Pacific11.4 South America11.5 Middle East & Africa

12 Strategic Benchmarking

13 Vendors Landscape13.1 Abbott Laboratories13.2 Affymetrix Incorporated13.3 Agendia N.V13.4 Agilent Technologies Inc.13.5 Amgen Inc.13.6 Asuragen Incorporated13.7 Bayer Healthcare Pharmaceuticals, LLC13.8 Celera Diagnostics LLC13.9 Celgene Corporation13.10 Roche Diagnostics Corporation13.11 Precision Biologics Incorporated13.12 Siemens Healthcare Diagnostics Inc.13.13 Sigma-Aldrich Corporation13.14 Johnson & Johnson13.15 Novartis AG13.16 Decode Genetics Inc.13.17 Exact Science Corporation13.18 Exagen Diagnostics Inc.13.19 GE Healthcare13.20 Genelex Corporation

For more information about this report visit https://www.researchandmarkets.com/r/37rw80

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/personalized-medicine-market-worth-3-92-trillion-by-2026---insights-into-diagnostics-medical-care-nutrition--wellness-and-therapeutics-301008591.html

SOURCE Research and Markets

Read the rest here:
Personalized Medicine Market Worth $3.92 Trillion by 2026 - Insights Into Diagnostics, Medical Care, Nutrition & Wellness, and Therapeutics - P&T...

Visualizing the Conversion of Adult Cells to Stem Cells – Technology Networks

Researchers from the group of Vlad Cojocaru together with colleagues the Max Planck Institute in Mnster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.A cells identity is driven by which DNA is read or not read at any point in time. Signaling in the cell to start or stop reading DNA happens through proteins called transcription factors. Identity changes happen naturally during development as cells transition from an undesignated cell to a specific cell type. As it turns out, these transitions can also be reversed. In 2012, Japanese researchers were awarded the Nobel prize for being the first to push a regular skin cell backwards to a stem cell.A fuller understanding of molecular processes towards stem cell therapiesUntil now, it is unknown how the conversion of a skin cell into a stem cell happens exactly, on a molecular scale. Fully understanding the processes with atomic details is essential if we want to produce such cells for individual patients in the future in a reliable and efficient manner, says research leader Vlad Cojocaru of the Hubrecht Institute. It is believed that such engineered cell types may in the future be part of the solution to diseases like Alzheimers and Parkinsons, but the production process would have to become more efficient and predictable.Pioneer transcription factorOne of the main proteins involved in the stem cell generation is a transcription factor called Oct4. It induces gene expression, or activity, of the proteins that reset the adult cell into a stem cell. Those genes induced are inactive in the adult cells and reside in tightly packed, closed states of chromatin, the structure that stores the DNA in the cell nucleus. Oct4 contributes to the opening of chromatin to allow for the expression of the genes. For this, Oct4 is known as a pioneer transcription factor.

The data from Cojocaru and his PhD candidate and first author of the publication Jan Huertas show how Oct4 binds to DNA on the so-called nucleosomes, the repetitive nuclear structures in chromatin. Cojocaru: We modelled Oct4 in different configurations. The molecule consists of two domains, only one of which is able to bind to a specific DNA sequence on the nucleosome in this phase of the process. With our simulations, we discovered which of those configurations are stable and how the dynamics of nucleosomes influence Oct4 binding. The models were validated by experiments performed by our colleagues Caitlin MacCarthy and Hans Schler in Mnster.One step closer to engineered factorsThis is the first time computer simulations show how a pioneer transcription factor binds to nucleosomes to open chromatin and regulate gene expression. Our computational approach for obtaining the Oct4 models can also be used to screen other transcription factors and to find out how they bind to nucleosomes, Cojocaru says.

Moreover, Cojocaru wants to refine the current Oct4 models to propose a final structure for the Oct4-nucleosome complex. For already almost 15 years now, we know that Oct4 together with three other pioneer factors transforms adult cells into stem cells. However, we still do not know how they go about. Experimental structure determination for such a system is very costly and time consuming. We aim to obtain one final model for the binding of Oct4 to the nucleosome by combining computer simulations with different lab experiments. Hopefully, our final model will give us the opportunity to engineer pioneer transcription factors for efficient and reliable production of stem cells and other cells needed in regenerative medicine.ReferenceHuertas et al. (2020) Nucleosomal DNA Dynamics Mediate Oct4 Pioneer Factor Binding. Biophysical Journal. DOI: https://doi.org/10.1016/j.bpj.2019.12.038

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Here is the original post:
Visualizing the Conversion of Adult Cells to Stem Cells - Technology Networks

Global Market Report on Research Antibodies and Reagents (2020 to 2025) – Featuring GE Healthcare, Merck KGaA & Abcam Among Others -…

The "Research Antibodies and Reagents Market by Product (Reagent [Sample Preparation (Media, Probe, Buffer), Antibody Production Reagent], Antibody [Type, Source, Research Area]), Technology (Western Blot, ELISA), Application, End User - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Research Antibodies and Reagents Market is Expected to Grow at a CAGR of 6% from 2019 to 2025 to Reach $14.56 Billion by 2025

The factors such as rising proteomics & genomic research studies, increase in the funding for research activities, and growing industry-academia collaborations - are driving the growth of the global research antibodies and reagents market.

The reagents segment is estimated to command the largest share of the global research antibodies and reagents market in 2019 and expected to continue its dominance during the forecast period mainly due to increasing use of reagents and kits in research assays and techniques.

The research antibodies and reagents market for the pharmaceutical and biotechnology industry (end user segment) segment is estimated to command the largest share of the global market in 2019. This is attributed to rising adoption of research antibodies & reagents in the proteomics research and drug discovery programs with the growing focus of industry vendors on the development of innovative therapeutic drugs for chronic diseases.

An in-depth analysis of the geographical scenario of the research antibodies & reagents market provides detailed qualitative and quantitative insights about the five major geographies along with the coverage of major countries in each region.

North America dominated the global research antibodies and reagents market in 2019, followed by Europe, and Asia-Pacific region. The large share of this region is mainly attributed to the availability of new technologies in the region, increasing research activities to assist the development of personalized medicine, and the direct presence of the key players.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Insights

4.1. Introduction

4.2. Market Dynamics

4.2.1. Drivers

4.2.1.1. Rising Proteomics and Genomics Research Studies

4.2.1.2. Increase in the Funding for Research Activities

4.2.1.3. Growing Industry-Academia Collaboration

4.2.2. Restraint

4.2.2.1. High Cost and Time Related to Identification and Development of Potential Antibodies

4.2.3. Opportunities

4.2.3.1. Rising Demand for Protein Therapeutics and Personalized Medicines

4.2.3.2. Rising Investment and Focus on Stem-Cell Research

4.2.3.3. Rising Need for New Biomarker Identification

4.2.3.4. Significant Opportunities from Emerging Asia-Pacific and Latin-American Markets

4.2.4. Challenges

4.2.4.1. Issues Related to Quality and Stability of Research Antibodies

4.2.4.2. Intense Pricing Pressure on Leading Players

5. Research Antibodies and Reagents Market, by Product

5.1. Introduction

5.2. Reagents

5.2.1. Sample Preparation Reagents

5.2.1.1. Media and Serum

5.2.1.2. Stains and Dyes

5.2.1.3 Probes

5.2.1.4. Buffers

5.2.1.5. Solvents

5.2.2. Antibody Production Reagents

5.2.2.1. Enzymes

5.2.2.2. Proteins

5.2.3. Other Research Reagents

5.3. Antibodies

5.3.1. Antibodies Market, by Type

5.3.1.1. Primary Antibody

5.3.1.2. Secondary Antibody

5.3.2. Antibodies Market, by Production Type

5.3.2.1. Monoclonal Antibody

5.3.2.2. Polyclonal Antibody

5.3.2.3. Antibody Fragments

5.3.3. Antibody Market, by Source

5.3.3.1. Mouse

5.3.3.2. Rabbit

5.3.3.3. Other Sources

5.3.4. Antibodies Market, by Research Area

5.3.4.1. Oncology

5.3.4.2. Infectious Diseases

5.3.4.3. Cardiovascular Disease

5.3.4.4. Immunology

5.3.4.5. Neurology

5.3.4.6. Stem Cell Research

5.3.4.7. Other Research Areas

6. Research Antibodies and Reagents Market, by Technology

6.1. Introduction

6.2 Western Blot

6.3. Immunofluorescence

6.4. Enzyme-Linked Immunosorbent Assay

6.5. Multiplex Immunosorbent Assay

6.6. Flow Cytometry

6.8. Immunoprecipitation (IP)

6.9. Other Technologies

7. Research Antibodies and Reagents Market, by Application

7.1. Introduction

7.2. Proteomics

7.3. Drug Discovery and Development

7.4. Genomics

8. Research Antibodies and Reagents Market, by End User

8.1. Introduction

8.2. Pharmaceutical and Biotechnology Industry

8.3. Academics and Research Institutes

Story continues

8.4. Contract Research Organizations

9. Research Antibodies and Reagents Market, by Geography

9.1. Introduction

9.2. North America

9.3. Europe

9.4. Asia-Pacific

9.5. Latin America

9.6. Middle East & Africa

10. Competitive Landscape

10.1. Introduction

10.2. Key Growth Strategies

10.3. Competitive Benchmarking

10.4. Market Share Analysis (2018)

11. Company Profiles

11.1. GE Healthcare

11.1.1. Business Overview

11.1.2. Financial Overview

11.1.3. Product Portfolio

11.2. Merck KGaA

11.3. Thermo Fisher Scientific Inc.

Read more:
Global Market Report on Research Antibodies and Reagents (2020 to 2025) - Featuring GE Healthcare, Merck KGaA & Abcam Among Others -...

The global cell expansion market is projected to reach US$ 42,837.11 Mn in 2027 from US$ 11,929.43 Mn in 2018 – Yahoo Finance

The cell expansion market is expected to grow with a CAGR of 15. 6% from 2019-2027. Driving factors include increasing adoption of regenerative medicines, rising prevalence of cancer. However, the risk contamination during cell expansion is expected to hamper the market during the forecast period.

New York, Feb. 17, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Expansion Market to 2027 - Global Analysis and Forecasts By Product ; Cell Type ; Application ; End User, and Geography" - https://www.reportlinker.com/p05862085/?utm_source=GNW

Cancer is one of the major cause of human death worldwide.In recent years, the cases of cancer have been increasing tremendously and the trend is anticipated to remain the same in the upcoming years.

According to the World Health Organization in 2018, approximately 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases would be diagnosed in the US.

Changes in lifestyle have resulted in more exposure to oncogenic factors.Cancer can be cured if diagnosed and treated at an initial stage.

Cancer sequencing using next-generation sequencing (NGS) methods provides more information. Additionally, cell expansion related procedures also aids in research, diagnostics and treatment of cancer.Furthermore, Asia Pacific region is also facing the problem of the growing prevalence of cancer.The top 15 countries with Cancer prevalence are Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia.

According to the National Institute of Cancer Prevention and Research (NICPR), in 2018, in India, total deaths due to cancer were 784,821.

The global Cell Expansion market is segmented by product, cell type, application, end user.Based on product, the cell expansion market is segmented into consumables and instruments.

In 2018, the consumables accounted for the largest market share in the global cell expansion market by product.These consumables are essential components of any laboratory experiment hence they are expected to witness significant growth during the forecast period.

Based on cell type, the cell expansion market has been segmented into human cell and animal cell.Furthermore based on application the cell expansion market has been segmented into Regenerative Medicine And Stem Cell Research, Cancer And Cell-Based Research and Other Applications.

Based in end user market is segmented into Biopharmaceutical And Biotechnology Companies, Research Institutes, cell banks and others.

Some of the essential primary and secondary sources included in the report are the National Institute of Cancer Prevention and Research (NICPR), Association for Management Education and Development, Center for Cancer Research, International Society for Stem Cell Research (ISSCR), American Association of Blood Banks (AABB), National Institute of Cancer Prevention and Research and others.Read the full report: https://www.reportlinker.com/p05862085/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read this article:
The global cell expansion market is projected to reach US$ 42,837.11 Mn in 2027 from US$ 11,929.43 Mn in 2018 - Yahoo Finance